[Summary] Provider of cancer/tumor risk assessment testing technologies and serv
MiRXES (Hangzhou) Biotechnology Co., Ltd. is a wholly-owned subsidiary of Singapore-based MIRXES, registered in Hangzhou (Xiasha Singapore Science and Technology Park). It is engaged in the research and application of miRNA detection technology in the life sciences and medical fields. Currently, the company is developing, producing, and selling non-invasive cancer diagnostic kits and providing (miRNA) testing services. The company has a world-class technology platform, an open and innovative corporate environment, scientific and rigorous management mechanisms, and international development opportunities (including opportunities for exchange, training, and work at the company's Singapore headquarters and U.S. branch). We sincerely invite professionals in technology development, market expansion, and medical registration to join us in jointly exploring the new generation non-invasive cancer diagnostics market. The company will provide competitive compensation and benefits as well as good personal development opportunities. The company was listed in Hong Kong on May 23, 2025, with stock code: 2629.HK. We welcome interested individuals to join MiRXES and create a bright future together.
What does MiRXES (Hangzhou) Biotechnology Co., Ltd. require? Who is MiRXES Biotech hiring? MiRXES Biotech recruitment: Business Management占比最多占26.2%,其次是Sales占26.2%. What education can get in at MiRXES Biotech? 大专占比最多占53.2%,其次是本科占25.4%. High education required at MiRXES Biotech? 硕士占10.3%,博士占3.2%. Work experience required at MiRXES Biotech? 1-3年占比最多占32.5%,其次是3-5年占31%. Where are the job locations at MiRXES Biotech? 杭州占比最多占41.3%,其次是九江占37.3%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows